We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tests on Day of Discharge Are Often Never Seen

By LabMedica International staff writers
Posted on 06 Sep 2012
The results of tests ordered on the day of a patient's discharge from the hospital made up a disproportionate number of tests that doctors never reviewed, according to a new study. More...


Researchers at the Australian Institute of Health Innovations (Sydney, Australia), and St Vincent's Hospital (Sydney, Australia) reviewed data on 662,858 clinical pathology tests ordered during 6,736 inpatient admissions at a single hospital. In all, more than one-third of admissions (37.7%) had at least one test that was not reviewed before discharge, and 28% had unreviewed results two months postdischarge. Of these, test results that were still pending--and thus, not yet available--at discharge accounted for only 28.6% of the tests that were not reviewed.

After analysis, the researchers found that although only a fraction of all tests were ordered on the day of discharge, those ordered on the last day of the hospital stay accounted for nearly half (46.8%) of tests that were not reviewed at discharge, and 41.1% of those that had not been looked at by two months. Of all of the unreviewed tests, 14.7% of those at discharge and 10.8% of those at two months later had abnormal test results. In all, about two-thirds of all unreviewed, abnormal results came from tests ordered on the day of discharge. The study was published online as a research letter on August 13, 2012, in Archives of Internal Medicine.

“When discharge dates are known, or the average length of stay for an admission is well defined, it would be possible to estimate the time available for review,” suggested lead author to Enrico Coiera, MBBS, PhD. “This information can be used to trigger computer alerts when tests are being ordered electronically. Alerts could advise clinicians either that it is unlikely those results will be posted before discharge, or that the tests simply have a high risk of being missed.”

Related Links:

Australian Institute of Health Innovations
St Vincent's Hospital



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.